# Chemotherapy Regimen Optimization Using a Two-Archive Multi-Objective Squirrel Search Algorithm
## 4 Experimental Setup and Results Analysis
### Results and Analysis
#### 4.4.3 Mild Chemotherapy Regimen  
In this subsection, we compare the chemotherapy regimen with the smallest cumulative bone marrow cell damage. Table 7 outlines the indicators obtained during the treatment process for each algorithm's chemotherapy regimen, while Figure 10 illustrates the trends in tumor cell and bone marrow cells over treatment sessions.  
As indicated in Table 7, the mild chemotherapy regimen obtained by the TA-MOSSA maintains relatively low concentrations of cisplatin and docetaxel within the patient's body, lower than those of other chemotherapy regimens. Moreover, it incurs the least cumulative damage to bone marrow cells, totaling only \(2.897\times 10^{10}\) cells. This ensures that, even at the lowest point during the entire treatment course, there are still \(6.116\times 10^{8}\) cells present in the bone marrow cell population, with an average level of \(7.277\times 10^{8}\) cells. In contrast, the lowest points in bone marrow cell counts for the remaining chemotherapy regimens are all below 50% of the initial values. The chemotherapy regimen obtained by the MOSSA, with the lowest efficacy, corresponds to a bone marrow cell count at its lowest point, close to 40%, similarly failing to demonstrate a good balance in conflicting optimization objectives and adequate consideration for protecting the bone marrow cell population.  
Additionally, Figure 10 indicates that the chemotherapy regimen obtained by the TA-MOSSA ensures that the bone marrow cell count remains higher than that of other chemotherapy regimens after each administration while still achieving significant tumor reduction, with only 28.64% of residual tumor cells. Conversely, the chemotherapy regimens  
\begin{table}
\begin{tabular}{c c c c c c c} \hline \hline
**Performance Metrics** & **TA-MOSSA** & **NSGA-II** & **MOPSO** & **Two\_Arch2** & **C-TAEA-II** & **MOSSA** \\ \hline Remained tumor cells (\(\times 10^{10}\)) & 2.864 & 2.080 & 1.861 & 2.684 & 1.756 & 1.410 \\ Proportion of remained tumor cells & 28.64\% & 20.80\% & 18.61\% & 26.84\% & 17.56\% & 14.10\% \\ Cumulative damaged bone marrow cells (\(\times 10^{10}\)) & 2.897 & 3.711 & 3.833 & 3.038 & 3.352 & 4.197 \\ Minimum counts of bone marrow cells (\(\times 10^{8}\)) & 6.116 & 4.455 & 4.644 & 5.807 & 4.371 & 4.362 \\ Average counts of bone marrow cells (\(\times 10^{8}\)) & 7.277 & 6.517 & 6.405 & 7.145 & 6.847 & 6.058 \\ Average dose concentration of cisplatin (mg/mL) & 1.909 & 2.255 & 2.499 & 1.966 & 2.602 & 2.983 \\ Average dose concentration of docetaxel (mg/mL) & 1.973 & 2.417 & 2.296 & 2.040 & 2.017 & 2.536 \\ \hline \hline \end{tabular}
\end{table}
Table 7: Performance metrics of mild chemotherapy treatment.  
Figure 10: Tumor cell and bone marrow cell population dynamics during mild chemotherapy treatment.  
obtained by MOPSO and the MOSSA result in substantial damage to bone marrow cells after two administrations between the 40 th and 80 th days, with a drop in bone marrow cell population approaching \(3\times 10^{8}\) This significantly impacts patient health and contradicts the original intention of mild chemotherapy regimens to ensure a high quality of life for patients.